BUREAU-VERITAS
20.1.2021 08:02:14 CET | Business Wire | Press release
Bureau Veritas , a world leader in testing, inspection and certification, announced today that it has completed the acquisition of Secura B.V. (starting with a majority stake), an independent service company specializing in cybersecurity services. Secura will be a cornerstone in the cybersecurity strategy of Bureau Veritas.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119006117/en/
Rising demand in digital security and new regulations drive a growing need for conformity assessments. As a result, Testing, Inspection and Certification (TIC) services for cybersecurity are an emerging market with substantial expected growth and significant momentum. In this promising new conformity market, Secura is a recognized cybersecurity player with a strong orientation toward TIC activities.
Established in 2000 in the Netherlands, Secura has 100 employees located in two technological centers in Eindhoven and Amsterdam. The company posted 2020 revenues slightly below €10 million.
With solid expertise and capabilities, Secura takes a holistic security approach in identifying and assessing cybersecurity risks according to standards, frameworks and certification programs. Secura’s mission is: “providing insight into your security.”
“Cybersecurity risks are growing for companies and individuals alike,” says Didier Michaud-Daniel, Chief Executive Officer of Bureau Veritas. “Personal and professional data and system protection have become a crucial challenge surrounding security, safety, and even business sustainability. This strategic alliance supports Bureau Veritas’ fast-paced development in the conformity assessment of non-physical assets. As we anticipate an acceleration of the current momentum of the cybersecurity TIC market in the coming years, Secura’s expertise will further reinforce our global offering addressing key geographies and industries. On behalf of the Bureau Veritas Executive Committee, I want to warmly welcome the Secura team.”
“Both Bureau Veritas and Secura see the big opportunity in cybersecurity in the coming decades,” adds Dirk Jan van den Heuvel, Managing Director of Secura . “There is a clear need to bring security to a higher level in many places in society. Joining forces with Bureau Veritas will undoubtedly boost our expansion and accelerate Secura’s capability in providing security expertise. We are confident that this strategic move will enable us to develop even faster in the future, as we benefit from the large footprint of Bureau Veritas and the integrity reputation it has earned from the world's leading corporations.”
Secura provides security testing, audit, training and certification services covering people, organization, and technology (networks, systems, applications and data). The company holds an extensive range of top-notch accreditations and licenses to operate to offer security testing and certification services according to a number of standards (including ISO 270011 , NIST CSF2 , OWASP ASVS3 , ISAE 3000/34024 , UNECE5 regulations, ETSI EN 303 6456 , IEC 624437 , Common Criteria8 ).
While firmly grounded in the European security market, the company now serves a diversified international client base and is active in all sectors, focusing on technology, energy, industrial, automotive, financial, public and healthcare markets.
1
ISO 27001 is the leading global standard on Information Security Management
2
The NIST Cybersecurity Framework (CSF) is a set of guidelines for private sector companies to follow to be better prepared in identifying, detecting, and responding to cyber-attacks
3
The OWASP Application Security Verification Standard (ASVS) is a detailed list of security requirements and guidelines that can be used to design, build and test highly secure applications
4
ISAE 3000/3402 are standards to provide assurance over non-financial information (3000) and Internal Controls (3402)
5
The United Nations Economic Commission for Europe (UNECE) regulations cover vehicle safety, environmental protection, energy efficiency and theft resistance
6
ETSI EN 303 645 provides baseline requirements for Consumer IoT devices
7
IEC 62443 standard specifies security capabilities for control system components and systems
8
The Common Criteria for Information Technology Security Evaluation (referred to as Common Criteria or CC) is an international standard (ISO/IEC 15408) for computer security certification
About Bureau Veritas
Bureau Veritas is a world leader in laboratory testing, inspection and certification services. Created in 1828, the Group has more than 75,000 employees located in more than 1,500 offices and laboratories around the globe. Bureau Veritas helps its clients improve their performance by offering services and innovative solutions, in order to ensure that their assets, products, infrastructure and processes meet standards and regulations in terms of quality, health and safety, environmental protection and social responsibility.
Bureau Veritas is listed on Euronext Paris and belongs to the Next 20 index.
Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit www.bureauveritas.com , and follow us on Twitter (@bureauveritas) and LinkedIn .
About Secura
Secura is an independent cybersecurity expert. Secura provides insights to protect valuable assets and data. We make cybersecurity tangible and measurable in the field of IT, OT and IoT. With security advice, testing, training and certification services, Secura approaches cybersecurity holistically and covers all aspects from people, policies and organizational processes to networks, systems, applications and data.
For more information, please visit: www.secura.com
Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210119006117/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
